Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 PARP inhibitors stumble in breast cancer.

Literature DB >> 21552220

PARP inhibitors stumble in breast cancer.

Malini Guha.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2011 PMID： 21552220 DOI： 10.1038/nbt0511-373

Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908

× No keyword cloud information.

2 in total

1. PARP inhibitors blaze a trail in difficult-to-treat cancers.

Authors: Jim Kling
Journal: Nat Biotechnol Date: 2009-09 Impact factor: 54.908

2. Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

Authors: Joyce O'Shaughnessy; Cynthia Osborne; John E Pippen; Mark Yoffe; Debra Patt; Christine Rocha; Ingrid Chou Koo; Barry M Sherman; Charles Bradley
Journal: N Engl J Med Date: 2011-01-05 Impact factor: 91.245

2 in total

49 in total

1. Re-evaluating PARP1 inhibitor in cancer.

Authors: Alexei Tulin
Journal: Nat Biotechnol Date: 2011-12-08 Impact factor: 54.908

2. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.

Authors: Anand G Patel; Silvana B De Lorenzo; Karen S Flatten; Guy G Poirier; Scott H Kaufmann
Journal: Clin Cancer Res Date: 2012-01-30 Impact factor: 12.531

Review 3. Diagnosing the decline in pharmaceutical R&D efficiency.

Authors: Jack W Scannell; Alex Blanckley; Helen Boldon; Brian Warrington
Journal: Nat Rev Drug Discov Date: 2012-03-01 Impact factor: 84.694

4. GFP labeling kinetics of triple-negative human breast cancer by a killer-reporter adenovirus in 3D Gelfoam® histoculture.

Authors: Shuya Yano; Kiyoto Takehara; Shinji Miwa; Hiroyuki Kishimoto; Hiroshi Tazawa; Yasuo Urata; Shunsuke Kagawa; Michael Bouvet; Toshiyoshi Fujiwara; Robert M Hoffman
Journal: In Vitro Cell Dev Biol Anim Date: 2017-02-23 Impact factor: 2.416

PARP inhibitors stumble in breast cancer.

1. PARP inhibitors blaze a trail in difficult-to-treat cancers.

2. Iniparib plus chemotherapy in metastatic triple-negative breast cancer.

1. Re-evaluating PARP1 inhibitor in cancer.

2. Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro.

Review 3. Diagnosing the decline in pharmaceutical R&D efficiency.

4. GFP labeling kinetics of triple-negative human breast cancer by a killer-reporter adenovirus in 3D Gelfoam® histoculture.

5. High-metastatic triple-negative breast-cancer variants selected in vivo become chemoresistant in vitro.

6. Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors.

7. Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity.

8. Targeting angiogenesis in metastatic breast cancer.

Review 9. Beyond DNA repair, the immunological role of PARP-1 and its siblings.

10. Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-Ribose) polymerase inhibition.